久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國Integrated Diagnostics
Integrated Diagnostics 正在開發基于血液的大規模分子診斷技術，該技術通過同時監測數十到數百個疾病標記物，實現重大疾病，如肺癌和阿爾茨海默氏癥的早期檢測。該公司由系統生物學先驅 Lee Hood 博士于 2009 年 10 月創立，公司正致力于通過采用尖端信息學技術進行生物標記物選擇，以及采用創新的具有類似抗體特性的合成診斷和治療劑——蛋白質催化的捕獲劑，開發新一代個體化醫療解決方案。Integrated Diagnostics 的目標是開發用于嚴重疾病早期檢測的新一代低成本、大規模診斷分析技術。該公司專注于從系統生物學角度研究包含蛋白質、基因及其他分子的疾病病理生理學分子網絡。投資者包括 InterWest Partners、The Wellcome Trust 和 BioTechCube Luxembourg。基礎知識產權由系統生物學研究所和加州理工學院獨家授權。






Integrated Diagnostics is developing large-scale, blood-based molecular diagnostics that detect important diseases like lung cancer and Alzheimer's at their earliest stages by simultaneously monitoring tens to hundreds of disease markers. The company, founded in October 2009 by systems biology pioneerDr. Lee Hood, is creating a new generation of personalized medical solutions using sophisticated informatics for biomarker selection and a novel class of synthetically created diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. Integrated Diagnostics' mission is to build a new generation of low-cost, large-scale diagnostic assays for early detection of serious diseases. The company is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners, The Wellcome Trust, and BioTechCube Luxembourg. Foundational intellectual property is exclusively licensed from the Institute of Systems Biology and Caltech.